OncoMatch/Multiple Myeloma (MM)/KRAS

Multiple Myeloma (MM)KRAS Clinical Trials

KRAS mutations occur in approximately 20–25% of multiple myeloma and are among the most common recurrent genomic alterations, typically arising as secondary events during disease progression. KRAS mutations may activate the RAS/MAPK pathway and confer resistance to some standard regimens. Trials investigate MEK/ERK pathway inhibitors, KRAS G12C-specific inhibitors in the subset with that variant, and combination strategies targeting RAS-driven myeloma.